Polatuzumabvedotin-piiq是CD79b定向的抗体-药物偶联物(ADC),由三个部分组成:1)对人CD79b特异的人源化免疫球蛋白G1(IgG1)单克隆抗体;2)小分子抗有丝分裂剂MMAE;3)蛋白酶可切割的接头马来酰亚胺基己酰基-缬氨酸-瓜氨酸-对氨基苄氧基羰基(mc-vc-PAB),其将MMAE共价附于泊洛妥珠单抗。 Polatuzumab vedotin-...
今日,罗氏旗下基因泰克公司宣布,美国FDA批准抗体偶联药物(ADC)Polivy(polatuzumab vedotin)与利妥昔单抗加环磷酰胺、多柔比星和泼尼松(R-CHP)联用,一线治疗弥漫性大B细胞淋巴瘤(DLBCL)患者。新闻稿指出,Polivy组合是近20年来FDA批准一线治疗DLBCL的首款新疗法,具有延缓疾病进展,降低患者和医疗健康系统负担的潜力。
【汇众医疗】罗氏旗下基因泰克淋巴瘤药物 Polatuzumab vedotin 获 FDA 优先审评资格 $罗氏控股(RHHBY)$罗氏旗下基因泰克今天宣布, FDA已经接受了该公司的生物技术许可申请( BLA ),并批准了与苯达莫司汀联合利妥昔单抗联合治疗复发或难治性(R/R)弥漫性大B细胞淋巴瘤的优先审评。 查看全文网页链接...
On June 10, 2019, The U.S. Food and Drug Administration (FDA) approved Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has ...
Background: Polatuzumab vedotin, the first FDA-approved antibody-drug conjugate (ADC) targeting CD79b, is utilized in the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), as well as relapsed or refractory (...
Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) received regulatory approvals for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on primary results from the randomized arms of the GO29365 study. After the randomized phase, 106 additional patients received pola...
Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic tran... Chen,Robert - 《Blood》 被引量: 148发表: 2012年 Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classi...
2019年6月10日,美国食品药品监督管理局批准加速批准泊洛妥珠单抗polatuzumab vedotin-piiq (POLIVY,Genentech,Inc .),这是一种CD79b导向的抗体-药物缀合物,用于与苯达莫司汀和利妥昔单抗产品联合使用,用于患有复发或难治性弥漫大B细胞淋巴瘤(DLBCL)的成年患者,未另行指定,在至少两次先前治疗后。
2023年4月19日,美国食品药品监督管理局批准泊洛妥珠单抗polatuzumab vedotin-piiq (Polivy,Genentech,Inc .)与利妥昔单抗产品、环磷酰胺、多柔比星和泼尼松(R-CHP)一起用于之前未经治疗的弥漫大B细胞淋巴瘤(DLBCL)、未另行指明(NOS)或高级B细胞淋巴瘤(HGBL)的成年患者,并且这些患者的国际预后指数(IPI)评分为2...
Polivy™ (polatuzumab vedotin-piiq) is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.